MEDULLARY CARCINOMA OF THE BREAST-EPIDEMIOLOGY, THE PATTERN OF CARE, AND TREATMENT OUTCOME: EXPERIENCE FROM THE TERTIARY CANCER CARE CENTER
Keywords:Medullary carcinoma, Breast, Triple-negative
Objectives: Medullary breast carcinoma is a very rare subtype of invasive ductal carcinoma breast which accounts for about 1–7% of all breast carcinoma. The natural history of this uncommon histological subtype is unknown because of the lack of adequate reported data in the literature and the rare variety of this tumor. In our retrospective analysis, we have tried to identify demographic clinicopathological features and treatment outcomes of this rare subtype.
Methods: Between January 2012 and December 2017, total of 1271 breast carcinoma cases were identified, and clinic pathological, demographic profile, and treatment received were recorded from the medical records file. American joint committee on Cancer tumor, node, and metastasis system was used for staging.
Results: Out of 1271 breast carcinomas, 19 histologically confirmed medullary carcinoma cases were identified and constitute about 1.5% of the total case. About 78% of patients were with Stage II and Stage III disease at the time of diagnosis. Eleven patients were initially treated with MRM followed by adjuvant chemotherapy and radiotherapy. Eight patients received neoadjuvant chemotherapy followed by surgery and radiotherapy. In addition to cytotoxic chemotherapy, two patients received trastuzumab also. None of the patients received hormone therapy as all the patients were hormone receptor-negative.
Conclusions: Out of all invasive carcinoma, approximately 1.5% of cases were medullary carcinoma. About 90% of cases were triple-negative. Triple-negative breast cancer is usually associated with poor outcomes but medullary carcinoma despite being triple-negative, patients with medullary carcinoma have a good chance of long-term survival.
Sharma K. Burden of non-communicable diseases in India: Setting priority for action. Int J Med Sci Public Health 2013;2:7-11. doi: 10.5455/ijmsph.2013.2.7-11
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917. doi: 10.1002/ijc.25516, PMID 21351269
Bera A, Banerjee C, Biswas L, Manna D. Epidemiology and prevalence of breast cancer: A retrospective study in a tertiary health care center in Kolkata over one decade. Int J Med Sci Public Health 2019;8:986-90. doi: 10.5455/ijmsph.2019.1028305102019
Romaniuk A, Lyndin M, Sikora V, Lyndina Y, Panasovska K. Histological and immunohistochemical features of medullary breast cancer. Folia Med Cracov 2015;52:41-8.
Provenzano E, Ulaner GA, Chin SF. Molecular classification of breast cancer. PET Clin 2018;13:325-38. doi: 10.1016/j.cpet.2018.02.004, PMID 30100073
Badowska-Kozakiewicz AM, Budzik MP, Liszcz A, Sobieraj MT, Czerw AI, Sobol M, et al. Clinicopathological factors associated with novel prognostic markers for patients with triple-negative breast cancer. Arch Med Sci 2019;15:1433-42. doi: 10.5114/aoms.2018.79568, PMID 31749871
Ridolfi RL, Rosen PP, Port A, Kinne D, Miké V. Medullary carcinoma of the breast: A clinicopathologic study with 10-year follow-up. Cancer 1977;40:1365-85. doi: 10.1002/1097-0142(197710)40:4<1365:aid-cncr2820400402>3.0.co;2-n, PMID 907958
Budzik MP, Sobieraj MT, Sobol M, Patera J, Czerw A, Deptała A, et al. Medullary breast cancer is predominantly triple-negative breast cancer histopathological analysis and comparison with invasive ductal breast cancer. Arch Med Sci 2022;18:432-9. doi: 10.5114/aoms.2019.86763, PMID 35316897
Mateo AM, Pezzi TA, Sundermeyer M, Kelley CA, Klimberg VS, Pezzi CM. A typical medullary carcinoma of the breast has similar prognostic factors and survival to a typical medullary breast carcinoma: 3,967 Cases from the national cancer data base. J Surg Oncol 2016;114:533-6. doi: 10.1002/jso.24367, PMID 27393599
Martinez SR, Beal SH, Canter RJ, Chen SL, Khatri VP, Bold RJ. Medullary carcinoma of the breast: A population-based perspective. Med Oncol 2011;28:738-44. doi: 10.1007/s12032-010-9526-z, PMID 20390465
Li CI. Risk of mortality by histologic type of breast cancer in the United States. Horm Cancer 2010;1:156-65. doi: 10.1007/s12672-010-0016-8, PMID 21761358
Park I, Kim J, Kim M, Bae SY, Lee SK, Kil WH, et al. Comparison of the characteristics of medullary breast carcinoma and invasive ductal carcinoma. J Breast Cancer 2013;16:417-25. doi: 10.4048/ jbc.2013.16.4.417, PMID 24454464
How to Cite
Copyright (c) 2022 DR. SHATARUPA DUTTA, DR SAPTARSHI BANERJEE, DR. ANJAN BERA, PROF. SRIKRISHNA MANDAL, CHANDRIMA BANERJEE
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.